Dana-Farber Cancer Institute | Strategic Alliance Partners

April 18, 2019

Ann S. LaCasce, MD, MMSc, director of Dana-Farber/Partners CancerCare Hematology-Medical Oncology Fellowship Program, institute physician, Dana-Farber Cancer Institute, and associate professor of medicine, Harvard Medical School, discusses key advances made in the mantle cell lymphoma (MCL) paradigm.

April 17, 2019

Ann S. LaCasce, MD, MMSc, highlights the therapeutic progress in the treatment of patients with mantle cell lymphoma , key remaining challenges, and where future research is headed.

April 16, 2019

Joyce F. Liu, MD, MPH, assistant professor of medicine, Harvard Medical School, and director of clinical research for gynecologic oncology at Dana-Farber Cancer Institute, discusses the use of PARP inhibitors in patients with recurrent ovarian cancer.

April 11, 2019

Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, Jerome and Nancy Kohlberg Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses atezolizumab plus bevacizumab in patients with non–clear cell renal cell carcinoma.

April 04, 2019

Suzanne George, MD, director of Clinical Research, Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, and an associate professor of medicine, Harvard Medical School, discusses the importance of collaboration in the treatment of patients with uterine sarcoma.

March 29, 2019

Although TMB is associated with responses to checkpoint inhibitor therapy, more research is needed to better understand how TMB interacts with other genomic correlates of the immune cycle before the biomarker can be incorporated into clinical practice.

March 26, 2019

Ursula A. Matulonis, MD, director, Gynecologic Oncology, Dana-Farber Cancer Institute, professor of medicine, Harvard Medical School, discusses individualized dosing of niraparib in the treatment of patients with ovarian cancer.

March 21, 2019

Matthew S. Davids, MD, MMSc, associate director, CLL Center, Dana-Farber Cancer Institute, assistant professor of medicine, Harvard Medical School, discusses challenges in the frontline treatment of patients with chronic lymphocytic leukemia.

March 11, 2019

Matthew S. Davids, MD, MMSc, discusses methods for choosing between frontline therapies for patients with newly diagnosed chronic lymphocytic leukemia and highlights anticipated research in the field.

March 09, 2019

Matthew S. Davids, MD, MMSc, associate director, CLL Center, Dana-Farber Cancer Institute, assistant professor of medicine, Harvard Medical School, discusses frontline treatment approaches for patients with chronic lymphocytic leukemia.

March 08, 2019

Panagiotis A. Konstantinopoulos, MD, PhD, director of Translational Research, Gynecologic Oncology, Dana-Farber Cancer Institute, associate professor of medicine, Harvard Medical School, discusses the role of immunotherapy in the treatment of patients with ovarian cancer.

March 08, 2019

Richard M. Stone, MD, discusses the therapeutic landscape for elderly patients with acute myeloid leukemia.

March 05, 2019

Susana Campos, MD, MPH, assistant professor of medicine, Harvard Medical School, and Dana-Farber Cancer Institute, discusses differences between PARP inhibitors in recurrent ovarian cancer.

February 28, 2019

Yana Pikman, MD, a physician in the Cancer and Blood Disorders Center at Dana-Farber Cancer Institute and instructor of pediatrics at Harvard Medical School, discusses the implications of a matched targeted therapy approach in pediatric leukemia.

February 12, 2019

Suzanne George, MD, director of Clinical Research, Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, and an associate professor of Medicine, Harvard Medical School, discusses ongoing trials in soft tissue sarcoma (STS).

February 06, 2019

Geoffrey R. Oxnard, MD, discusses the use of cell-free DNA as a potential method of cancer detection and subsequent assessment of treatment response in patients with solid and hematologic malignancies.

February 05, 2019

Because specific risk-reducing interventions may be available, it is important to identify individuals with germline variants in cancer susceptibility genes.

January 31, 2019

Huma Q. Rana, MD, discusses the evolution of genetic testing in ovarian cancer and the genes that are associated with an increased risk of subsequent cancer development.

January 29, 2019

Susana Campos, MD, MPH, highlights the success with PARP inhibitors in the relapsed and maintenance ovarian cancer settings.

January 29, 2019

Stephanie K. Dougan, PhD, discusses research aimed at assessing ways of augmenting T-cell immunity in pancreatic cancer.